Form 4: Pfizer EVP Lankler Exercises SARs, Adjusts Holdings

Pfizer Executive Vice President Douglas M. Lankler reported the exercise of stock appreciation rights and subsequent share adjustments for tax and exercise price obligations.

Summary

• Douglas M. Lankler, Executive Vice President of Pfizer Inc., reported transactions involving the company's common stock on February 25, 2026.
• Lankler acquired 122,907 shares of common stock through the earn-out of stock appreciation rights (SARs), including dividend equivalents, at an exercise price of $33.82 per share.
• Concurrently, 2,198 shares were disposed of at $27.09 per share to satisfy tax obligations related to the SAR earn-out.
• An additional 116,811 shares were disposed of at $26.92 per share to cover the exercise price payment for the SARs.
• Following these transactions, Lankler directly holds 163,177 shares of Pfizer common stock and indirectly holds 2,083 shares through a Rule 16b-3 Plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting a routine compensation transaction where an executive realized value from long-term incentives, which is generally a positive for executive retention and alignment, despite the immediate sale of shares to cover costs.

Positives

• Executive Vice President Douglas M. Lankler realized value from his stock appreciation rights, indicating a successful vesting and exercise of long-term incentive compensation.
• The exercise of SARs and subsequent share acquisition increases the executive's direct ownership in the company, aligning his interests with shareholders.

Negatives

• A significant portion of the acquired shares (116,811 shares) was immediately disposed of to cover the exercise price, and another portion (2,198 shares) for tax obligations, reducing the net increase in direct beneficial ownership.

Industry Context

StockSavvy.ai notes that executive compensation, particularly through equity-based incentives like Stock Appreciation Rights, is a standard practice across the pharmaceutical industry to align management interests with long-term shareholder value. These routine Form 4 filings provide transparency into how executives manage their vested equity.

Related Party Transactions

• The transactions involve an executive (Douglas M. Lankler) and the company (Pfizer Inc.), which are considered related party transactions under SEC rules, specifically the exercise of stock appreciation rights and subsequent share adjustments.

Stakeholder Impact

• Shareholders: Provides transparency into executive compensation and share ownership, potentially signaling management's confidence or need for liquidity. The net increase in direct holdings is small after covering costs.
• Management: Douglas M. Lankler realized value from his long-term incentive compensation.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the exercise of stock appreciation rights and subsequent share sales to cover taxes and exercise costs. Such transactions are generally expected and do not typically indicate a change in the company's fundamental outlook or warrant a change in investment recommendation. The executive's net beneficial ownership remains substantial, suggesting continued alignment with shareholder interests.

Keywords

Pfizer, PFE, Form 4, Insider Trading, Stock Appreciation Rights, SARs, Executive Compensation, Douglas M. Lankler, Share Ownership, SEC Filing